What is Trucheck™?

Trucheck™ has 92.1% sensitivity for detecting cancer in all its stages and 93.1% accuracy in determining the tissue or organ where a malignant process develops with a positive test result. Trucheck™ is so universal that it detects cancer at any stage of development, even at the earliest stage before the patient experiences any symptoms or complaints.

---

Who is the Trucheck™ test for?

Every person who wants to know if an oncological process is developing asymptomatically in his body, but especially if:

• they have a family history
• they are aged over 45-50
• they are from a high-risk group (e.g. long-term smoker, worked with heavy metals or exposed to a lot of sun)

The Trucheck test is not suitable for people who already have a history of cancer. It is intended for healthy individuals who do not have symptoms and have not had cancer in the past.

---

ADVANTAGES

The Trucheck™ intelli blood biopsy detects over 70 types of cancer with a single blood testwhile traditional invasive biopsy can detect only one type of cancer and has a high risk of a false negative. This revolutionary technology is risk-free and highly accurate. The blood biopsy method developed by Datar Cancer Genetics, which is done in Hill Clinic is effective and minimally invasive. This test is an excellent option for screening, diagnosis, personalized treatment, follow-up and/or prediction of cancer recurrence.

---

The US Food and Drug Administration (FDA) has declared Datar Cancer Genetics' tests a breakthrough in medical technology of special significance.

---

METHOD

Circulating tumor cell (CTC) enrichment: Conventional means of CTC enrichment rely on either immunoaffinity capture (magnetic) or separation based on size and charge(microfluidic devices). The former faces limitations with CTCs that express a small amount of an epitope or those that are isolated in clusters with epitope-expressing cells. In addition to low sensitivity, this also results in low specificity by enriching incidental non-malignant cells that express the detection epitope. The latter has a low capture rate of CTCs outside the working size/loading range of the device and can also enrich non-malignant cells with parameters consistent with detection.

Unlike other methods, Trucheck uses an epigenetically activating environment (EAM) that negatively enriches CTCs through the hallmark of cancer to avoid cell death (apoptosis). Every cell in the human body has a certain lifespan that is genetically programmed. When isolated peripheral blood mononuclear cells (PBMCs) are treated with EAM, all non-malignant cells are killed by their functional apoptosis mechanism, while all malignant cells survive.

These circulating tumor cell CTCs can be found in cancer patients and do not exist in healthy people. A blood biopsy can determine which organ these cells come from, ie. to indicate the exact location of the tumor. Detected cancer cells are examined for number, size and characteristics, and the whole process takes only a few days.

The blood biopsy method provides an extremely fast diagnosis and corresponding treatment of cancer in the earliest phase which gives an optimal prognosis for the patient's survival and ensures their quality of life..

---

Example: the accuracy of Trucheck™ Prostate is over 99%, with no risk of false positive results.

You can see how to prepare for the test here..

Tests:

Trucheck™ intelli 1200EUR

SCHEDULE YOUR APPOINTMENT FOR AN EARLY CANCER SCREENING BLOOD TEST NOW: 024393131